CNC vs OSCR

Key Takeaways

• Centene (CNC) is a managed care giant serving approximately 27.6 million members, primarily through government-sponsored programs such as Medicaid and Medicare, while Oscar Health (OSCR) is a technology-driven health insurer focused on the individual and small group markets with roughly 2 million members.
• Both companies faced significant headwinds in 2025 from elevated medical costs and shifting market morbidity, but each has charted a distinct recovery path with sharply different scale, business models, and risk profiles.
• Centene generated approximately $195 billion in full-year 2025 revenue with a market capitalization near $31 billion, whereas Oscar Health reported roughly $11.7 billion in revenue with a market cap of approximately $8.5 billion — a notable scale disparity.
• Oscar Health's stock has posted a year-to-date gain of roughly 96% in 2026, significantly outpacing Centene's recovery, though Oscar's beta of approximately 2.34 signals considerably higher volatility.
• Both companies project a return to profitability in 2026: Centene guided for adjusted diluted earnings per share (EPS) above $3.00, while Oscar Health guided for operating income between $250 million and $450 million.
• The relative performance contrast between these two names reflects different stages of corporate maturity, with Centene viewed as a value-recovery play and Oscar Health as a higher-growth, higher-risk turnaround story.

Introduction

The managed care sector has experienced considerable turbulence over the past year, as elevated medical utilization, shifting post-pandemic enrollment patterns, and regulatory uncertainty challenged even the largest health insurers. Against this backdrop, comparing CNC (Centene Corporation) and OSCR (Oscar Health, Inc.) offers a compelling lens through which to evaluate two very different approaches to navigating the same industry storm. Centene, a dominant force in government-sponsored health coverage with nearly three decades of operating history, contrasts sharply with Oscar Health, a comparatively younger, technology-first insurer that has only recently approached consistent profitability. This comparison may prove useful for investors seeking to understand how scale, strategy, and market positioning influence relative performance in the current environment.

CNC Overview and Recent Performance

Centene Corporation is one of the largest managed care organizations in the United States, specializing in government-sponsored healthcare programs including Medicaid, Medicare, and the Health Insurance Marketplace. The company serves approximately 27.6 million members as of its most recent reporting period, making it a critical intermediary between federal and state governments and healthcare providers. In recent months, Centene's stock has staged a notable recovery from the deep sell-off that occurred in mid-2025, when the company abruptly withdrew its financial guidance after an independent actuarial review revealed materially lower-than-expected marketplace enrollment growth and significantly higher morbidity (the frequency of illness within a covered population) across key states.

For the full year 2025, Centene reported total revenues of approximately $194.8 billion, with a health benefits ratio (HBR — medical costs as a percentage of premium revenue) of 91.9%. The company recorded a GAAP (Generally Accepted Accounting Principles) diluted loss per share of $13.53, driven in part by non-cash impairment charges related to the divestiture of its remaining Magellan Health businesses. On an adjusted basis, however, Centene delivered diluted EPS of $2.08. Management has provided 2026 guidance calling for adjusted diluted EPS greater than $3.00, reflecting expectations of meaningful margin improvement as repricing actions take effect and Medicaid cost trends stabilize. The company's forward price-to-earnings (P/E) ratio of approximately 18 reflects a market cautiously pricing in this recovery, while its price-to-sales ratio near 0.16 underscores the deep-value orientation of its current valuation.

OSCR Overview and Recent Performance

Oscar Health, Inc. is a healthcare technology company that offers individual and family health insurance plans, small group products, and a technology platform (+Oscar) that serves other participants in the healthcare ecosystem. Founded in 2012, the company has positioned itself as a tech-enabled disrupter in the insurance market, leveraging artificial intelligence and a consumer-centric digital experience to differentiate itself from legacy carriers. Recent trading activity reflects a dramatic shift in market sentiment, with Oscar Health's stock price more than doubling since the start of 2026.

For the full year 2025, Oscar Health reported total revenues of approximately $11.7 billion, up from $9.2 billion in 2024, driven by membership growth. The company's medical loss ratio (MLR — the percentage of premiums spent on medical claims) rose to 87.4% from 81.7% in the prior year, reflecting higher average market morbidity and increased risk adjustment transfer accruals. As a result, Oscar swung from a modest operating profit of $57.3 million in 2024 to an operating loss of approximately $396.4 million in 2025. Net loss attributable to Oscar Health was $443.2 million, or $1.69 per diluted share. Looking ahead, management has guided for 2026 revenue of $18.7 to $19.0 billion, an MLR of 82.4% to 83.4%, and operating income between $250 million and $450 million — a substantial projected turnaround. The company's SG&A (Selling, General, and Administrative) expense ratio improvement from 19.1% in 2024 to 17.5% in 2025 illustrates ongoing operating leverage, a trend management expects to continue.

Trending AI Robots

In a market environment where sector rotations and macro uncertainty can shift rapidly, many traders are turning to AI-powered tools for data-driven decision-making. Tickeron's Trending AI Robots page curates the platform's best-performing AI trading bots from a universe of hundreds available, each designed to trade thousands of different tickers across varied timeframes and strategies. These bots span multiple trading styles — from aggressive high-frequency 5-minute and 15-minute agents to more deliberate swing-trading and trend-following models — and their performance statistics, including annualized returns, Sharpe ratios, and drawdown metrics, are transparently displayed. Only the bots most suited to prevailing market conditions earn a place in this curated section, offering traders a streamlined way to identify strategies that align with their risk tolerance and objectives. Explore the Trending AI Robots page to see which strategies are currently leading.

Head-to-Head Comparison

The most striking contrast between these two companies lies in scale and revenue composition. Centene generated roughly 16 times the revenue of Oscar Health in 2025, reflecting its deep penetration of the Medicaid and Medicare markets, which provide a degree of revenue stability from government contracts. Oscar Health, conversely, derives its membership predominantly from the individual market, where consumer choice, premium pricing, and regulatory shifts — such as changes to enhanced premium tax credits — directly influence enrollment and retention.

Growth dynamics also diverge meaningfully. Oscar Health is projecting full-year 2026 revenue of approximately $18.85 billion at the midpoint, representing roughly 60% year-over-year growth, propelled by record membership and expanded market presence. Centene, by comparison, guided for 2026 revenues between $186.5 billion and $190.5 billion, which represents a modest contraction from 2025 levels as the company digests the divestiture of Magellan Health and allows lower-margin business lines to roll off. This contrast frames Oscar Health as a growth story and Centene as a margin-recovery narrative.

Risk profiles present another important trade-off. Centene carries approximately $17.5 billion in long-term debt with a debt-to-capital ratio above 45%, introducing financial leverage into the recovery equation. Oscar Health's balance sheet is comparatively lighter, though its higher beta and reliance on a single market segment mean its equity is considerably more volatile. Additionally, Centene faces ongoing securities litigation related to its 2025 guidance withdrawal, which could remain an overhang in the near term. Oscar Health's risk is more operational — its turnaround thesis depends heavily on achieving the guided MLR improvement and sustaining membership momentum.

Sector exposure is another differentiator. Centene's heavy weighting toward Medicaid exposes it to policy risk, including potential work requirements that could reduce enrollment beginning in 2027. Oscar Health, with its concentration in the individual market, is more sensitive to changes in the ACA (Affordable Care Act) regulatory framework and premium subsidy structures.

Tickeron AI Verdict

Based on observable factors — including trend consistency, relative momentum, growth trajectory, and risk-adjusted positioning — Tickeron's AI framework would likely find a nuanced case for each stock depending on the strategy employed. Oscar Health's strong price momentum and membership growth trajectory may appeal to trend-following AI models that prioritize directional strength and volume confirmation. However, its elevated beta and dependence on a successful 2026 margin turnaround introduce variability that more conservative, stability-oriented algorithms would weigh against it. Centene, with its deep-value metrics, forward P/E near 18, and clearly articulated path to earnings recovery above $3.00 per share, may register more favorably on mean-reversion and value-rotation signals. In probability-weighted terms, a balanced AI assessment would likely acknowledge Oscar Health's superior recent momentum while recognizing Centene's more established earnings base, diversified revenue streams, and lower equity volatility as factors that may support more consistent risk-adjusted positioning over a multi-quarter horizon.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations